AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst
AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant gain in overall survival, the company said. AbbVie and partner Genmab said they plan to consult regulators on the next steps.
